Shire Continues to Deliver Excellent Growth From Cor...(.9 million and $26.0 million have been ...),Health

Date:10/30/2009

.9 million and $26.0 million have been reclassified from Research and development to Selling, general and administrative costs for the three and nine months to September 30, 2008 respectively. Unaudited US GAAP results for the three months and nine months to September 30, 2009 Consolidated Statements of Operations (continued) 3 months to 3 months to 9 months to 9 months to September September September September 30, 2009 30, 2008 30, 2009 30, 2008 Earnings/(loss) per ordinary share - basic Earnings/(loss) from continuing operations 11.0c (6.3c) 61.1c 2.9c Loss from discontinued operations - (0.2c) (2.3c) (0.2c) Earnings/(loss) per ordinary share - basic 11.0c (6.5c) 58.8c 2.7c Earnings/(loss) per ADS - basic 33.0c (19.5c) 176.4c 8.1c Earnings/(loss) per ordinary share - diluted Earnings/(loss) from continuing operations 10.9c (6.3c) 60.3c 2.9c Loss from discontinued operations - (0.2c) (2.3c) (0.2c) Earnings/(loss) per ordinary share - diluted 10.9c (6.5c) 58.0c 2.7c Earnings/(loss) per ADS - diluted 32.7c (19.5c) 174.0c 8.1c Weighted average number of shares (millions): Basic 540.6 540.3 540.0 542.6 Diluted 548.3 540.3 547.1 545.3 Unaudited US GAAP results for the three months and nine months to September 30, 2009 Consolidated Statements of Cash Flows 3 months 3 months 9 months 9 months
'/>"/>

SOURCE Shire Plc Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33
Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease